Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.

Conclusion: FGFR1 and RUNX1 may be potential therapeutic targets for clinical trials. More accumulation of cases is also needed to determine whether allo-HSCT could be an optimal approach. PMID: 33491601 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research